## **AMENDMENTS TO THE CLAIMS**

## <u>Listing of Claims</u>:

## 1-28. (Cancelled)

- 29. (Currently Amended) A method of preventing and/or treating vasculitis comprising administering an interleukin-6 (IL-6) antagonist to a subject in need thereof.
- 30. (Withdrawn) A method of preventing and/or treating vasculitis having resistance to steroids and/or immunosuppressants, comprising administering an interleukin-6 (IL-6) antagonist to a subject in need thereof.
- 31. (Previously Presented) The method according to claim 29 wherein said vasculitis is polyarteritis nodosa.
- 32. (Withdrawn) The method according to claim 29 wherein said vasculitis is the aortitis syndrome.
- 33. (Withdrawn) The method according to claim 29 wherein said vasculitis is vasculitis associated with immunological abnormalities.
- 34. (Previously Presented) The method according to claim 29 wherein said IL-6 antagonist is an antibody against IL-6 receptor.
- 35. (Original) The method according to claim 34 wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.
- 36. (Original) The method according to claim 34 wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.
- 37. (Withdrawn) The method according to claim 34 wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.
- 38. (Previously Presented) The method according to claim 34 wherein said antibody against IL-6 receptor is a recombinant antibody.

- 39. (Original) The method according to claim 36 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.
- 40. (Withdrawn) The method according to claim 37 wherein said monoclonal antibody against mouse IL-6 receptor is MR1 antibody.
- 41. (Previously Presented) The method according to claim 34 wherein said antibody against IL-6 receptor is a chimeric antibody, humanized antibody, or a human antibody against IL-6 receptor.
- 42. (Original) The method according to claim 41 wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody.